ストックスクリーナーアプリを入手
8.20
0.61%
0.05
プレマーケット:
7.92
-0.28
-3.41%
前日終値:
$8.15
開ける：
$8.32
24時間の取引高:
1.13M
Relative Volume:
1.69
時価総額：
$5.58B
収益：
$8.62B
当期純損益:
$573.80M
株価収益率:
11.60
EPS:
0.707
ネットキャッシュフロー:
$680.05M
1週間 パフォーマンス:
+8.75%
1か月 パフォーマンス:
+11.87%
6か月 パフォーマンス:
-11.35%
1年 パフォーマンス:
-24.42%
1日の値動き範囲:
$8.135
$8.37
1週間の範囲:
$7.56
$8.37
52週間の値動き範囲:
$6.96
$10.88
Grifols Sa Adr Stock (GRFS) Company Profile
Compare GRFS vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
8.20 | 5.27B | 8.62B | 573.80M | 680.05M | 0.707 |
LLY
Lilly Eli Co
|
1,154.97 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.82 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
257.41 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
129.79 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
158.44 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-12 | 再開されました | Morgan Stanley | Overweight |
| 2024-03-12 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-04-12 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-03 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-16 | アップグレード | Barclays | Underweight → Equal Weight |
| 2023-01-18 | アップグレード | Jefferies | Hold → Buy |
| 2022-04-08 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-11-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-10-19 | ダウングレード | Barclays | Overweight → Underweight |
| 2021-10-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-06-14 | アップグレード | Deutsche Bank | Hold → Buy |
| 2021-04-20 | 開始されました | Deutsche Bank | Hold |
| 2021-03-23 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-03-11 | アップグレード | HSBC Securities | Hold → Buy |
| 2020-10-01 | アップグレード | Citigroup | Sell → Neutral |
| 2020-06-09 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-06-09 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-03-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-06-27 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-02-08 | ダウングレード | Berenberg | Buy → Hold |
| 2018-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2018-06-01 | 開始されました | Barclays | Overweight |
| 2017-10-31 | 開始されました | Citigroup | Buy |
| 2017-06-30 | ダウングレード | Goldman | Buy → Neutral |
| 2017-04-06 | 開始されました | BofA/Merrill | Buy |
| 2017-01-03 | アップグレード | JP Morgan | Neutral → Overweight |
| 2016-02-09 | アップグレード | Berenberg | Hold → Buy |
| 2016-01-04 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2015-12-02 | ダウングレード | HSBC Securities | Buy → Hold |
| 2015-11-20 | ダウングレード | Berenberg | Buy → Hold |
| 2015-04-28 | ダウングレード | Berenberg | Buy → Hold |
すべてを表示
Grifols Sa Adr (GRFS) 最新ニュース
Grifols SA (GRFS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Grifols, S.A. (GRFS) Stock Price, News, Quote & History - Yahoo! Finance Canada
[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Grifols doses first patients in two phase 3 immunoglobulin trials By Investing.com - Investing.com UK
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - TradingView
G0FB Forecast — Price Target — Prediction for 2027 - TradingView
GRFSGrifols SA ADR Options - Finviz
G0F Forecast — Price Target — Prediction for 2027 - TradingView
Grifols operations profile, Sunday focus on plasma and strategy - ad-hoc-news.de
A1C3HH Forecast — Price Target — Prediction for 2027 - TradingView
Grifols, S.A. Class A Actuals & Estimates (BME:GRF) - TradingView
A1J1E2 Forecast — Price Target — Prediction for 2027 - TradingView
Grifols, S.A. Sponsored ADR Class B Actuals & Estimates (NASDAQ:GRFS) - TradingView
Grifols holds technical support, shares trade in a tight Nasdaq range - AD HOC NEWS
Grifols S.A. Stock (ES0171996087): IBEX 35 plasma specialist in focus after modest gain - Ad-hoc-news.de
GRIFOLS SA-ADR (GRFS) Stock Chart - ChartMill
Grifols Shares Edge Lower as Stock Tests Key Support ZoneVolatility Smirk - newsline.com
Grifols ADR (GRFS) Gains 1.47% as Shares Hold Above Key Support LevelSector Leader Stocks - newsline.com
Grifols S.A. stock (ES0171996087): Q1 2026 figures and rising short interest keep focus on Spanish p - AD HOC NEWS
Grifols S.A. stock (ES0171996087): Spain plasma specialist in focus after volatile trading week - AD HOC NEWS
GRFS Stock Price, Quote & Chart | GRIFOLS SA-ADR (NASDAQ:GRFS) - ChartMill
Grifols S.A. stock (ES0171996087): Debt reduction deal, Q1 update and what matters for US investors - AD HOC NEWS
Grifols S.A. stock (ES0171996087): plasma specialist regains momentum after earnings update - AD HOC NEWS
Grifols S.A. stock (ES0171996087): plasma specialist back in focus after debt and governance reset - AD HOC NEWS
Grifols SA stock (ES0171996087): AGM plans and Moody’s outlook shift put debt and governance back - AD HOC NEWS
Grifols SA stock (ES0171996087): shareholders eye 2026 AGM after Moody’s outlook boost - AD HOC NEWS
Brandes reports 24.31% stake in Grifols (NASDAQ: GRFS) in Schedule 13G/A - Stock Titan
Earnings call transcript: Grifols Q1 2026 sees mixed results with EPS beat - Investing.com
Grifols S.A. stock (ES0171996087): Leading player in plasma-derived medicines - AD HOC NEWS
Grifols S.A. stock (ES0171996087): Plasma therapy specialist faces pricing and regulatory headwinds - AD HOC NEWS
Earnings call transcript: Grifols Q1 2026 results show mixed signals, revenue miss - Investing.com
Grifols Q1 Earnings Call Highlights - Barchart
Mittleman Value Partners 2025 Year-End & Q1 2026 Investment Review - Seeking Alpha
Grifols (NASDAQ: GRFS) 2025 revenue rises as leverage and risk factors stay elevated - Stock Titan
CapEx per share of Grifols, S.A. Sponsored ADR Class B – LSX:A1J1E2 - TradingView
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
Grifols S.A. stock (ES0171996087): Why does its plasma therapy model matter more for U.S. investors - AD HOC NEWS
Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance UK
Grifols S.A. Stock: Navigating Debt Reduction Through US Biopharma IPO Plans Amid Market Pressures - AD HOC NEWS
Grifols S.A. stock surges as board approves potential US IPO for biopharma unit, unlocking value in - AD HOC NEWS
Grifols Sa Adr (GRFS) 財務データ
収益
当期純利益
現金流量
EPS
0.95%
0.00%
大文字化:
|
ボリューム (24 時間):